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BACKGROUND
Whether an insulin infusion should be used for tight control of hyperglycemia in 
critically ill children remains unclear.
METHODS
We randomly assigned children (≤16 years of age) who were admitted to the pedi-
atric intensive care unit (ICU) and were expected to require mechanical ventilation 
and vasoactive drugs for at least 12 hours to either tight glycemic control, with a 
target blood glucose range of 72 to 126 mg per deciliter (4.0 to 7.0 mmol per liter), 
or conventional glycemic control, with a target level below 216 mg per deciliter 
(12.0 mmol per liter). The primary outcome was the number of days alive and free 
from mechanical ventilation at 30 days after randomization. The main prespecified 
subgroup analysis compared children who had undergone cardiac surgery with those 
who had not. We also assessed costs of hospital and community health services.
RESULTS
A total of 1369 patients at 13 centers in England underwent randomization: 694 to 
tight glycemic control and 675 to conventional glycemic control; 60% had undergone 
cardiac surgery. The mean between-group difference in the number of days alive and 
free from mechanical ventilation at 30 days was 0.36 days (95% confidence interval 
[CI], −0.42 to 1.14); the effects did not differ according to subgroup. Severe hypogly-
cemia (blood glucose, <36 mg per deciliter [2.0 mmol per liter]) occurred in a higher 
proportion of children in the tight-glycemic-control group than in the conventional-
glycemic-control group (7.3% vs. 1.5%, P<0.001). Overall, the mean 12-month costs 
were lower in the tight-glycemic-control group than in the conventional-glycemic-
control group. The mean 12-month costs were similar in the two groups in the 
cardiac-surgery subgroup, but in the subgroup that had not undergone cardiac sur-
gery, the mean cost was significantly lower in the tight-glycemic-control group than 
in the conventional-glycemic-control group: −$13,120 (95% CI, −$24,682 to −$1,559).
CONCLUSIONS
This multicenter, randomized trial showed that tight glycemic control in critically 
ill children had no significant effect on major clinical outcomes, although the inci-
dence of hypoglycemia was higher with tight glucose control than with conventional 
glucose control. (Funded by the National Institute for Health Research, Health 
Technology Assessment Program, U.K. National Health Service; CHiP Current Con-
trolled Trials number, ISRCTN61735247.)
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on January 15, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;2 nejm.org january 9, 2014108
Hyperglycemia is a common compli-cation in critical illness and is associated with adverse outcomes.1-5 Single-center, 
randomized trials have shown that reduction of 
blood glucose to normal levels with the use of 
insulin reduces morbidity and mortality among 
adults in surgical intensive care units (ICUs),6 
with similar effects on morbidity but not on mor-
tality among adults in nonsurgical ICUs.7 How-
ever, two meta-analyses8,9 have failed to show a 
benefit, and a large, international, multicenter 
trial showed that tight glycemic control increased 
mortality.10
Data on tight glucose control with the use of 
insulin in critically ill children have been lacking. 
One trial conducted in a single center, involving 
primarily patients who had undergone cardiac 
surgery,11 did not include a full economic evalu-
ation — a limitation that has also been seen in 
studies involving critically ill adults. The aim of 
the current trial, the Control of Hyperglycaemia 
in Paediatric Intensive Care (CHiP) trial, was to 
assess whether tight glycemic control with the 
use of an insulin infusion in children admitted 
to pediatric ICUs after cardiac surgery or for 
other reasons reduces mortality and morbidity 
and is cost-effective.
Me thods
STUDY OVERSIGHT
We conducted a parallel-group, randomized, con-
trolled trial involving children admitted to 13 pe-
diatric ICUs in England. The trial was approved 
in 2007 by a National Health Service (NHS) mul-
ticenter research ethics committee. The protocol, 
which has been published previously,12 is avail-
able, along with the statistical analysis plan, with 
the full text of this article at NEJM.org. All the 
authors were involved in designing the study and 
preparing the manuscript and vouch for the ac-
curacy and completeness of this report, as well as 
the fidelity of this report to the study protocol. 
Written informed consent was obtained from 
each child’s parent or legal surrogate. There was 
no commercial support for the trial.
PATIENTS
Children were eligible if they were between 36 
weeks of corrected gestational age and 16 years 
of age, if they had been admitted to a pediatric 
ICU, and if they had an arterial catheter in place 
and were receiving mechanical ventilation and 
vasoactive drugs after an injury or major surgery 
or for a critical illness, with an anticipated dura-
tion of treatment of at least 12 hours. Children 
were excluded if they had diabetes mellitus, if 
they had a confirmed or suspected inborn error 
of metabolism, if withdrawal of treatment was 
being considered, if they had been in a pediatric 
ICU for more than 5 days, or if they had already 
participated in the current trial.
TREATMENT
The randomization of patients to conventional 
glycemic control or tight glycemic control was 
performed by means of a central computerized 
system with the use of a minimization algo-
rithm.12 In the conventional-glycemic-control 
group, insulin in saline was infused intravenous-
ly when blood glucose levels exceeded 216 mg per 
deciliter (12.0 mmol per liter) in two consecutive 
blood samples obtained at least 30 minutes apart 
and was discontinued when blood glucose levels 
fell below 180 mg per deciliter (10.0 mmol per 
deciliter). In the tight-glycemic-control group, an 
intravenous infusion of insulin in saline was ad-
justed to maintain blood glucose levels in the range 
of 72 to 126 mg per deciliter (4.0 to 7.0 mmol per 
liter). In both groups, management was guided 
by treatment algorithms developed for the study.12 
All other aspects of patient care and nutrition 
were the responsibility of the treating clinicians.
Blood samples for glucose measurement were 
obtained from arterial catheters whenever pos-
sible. Blood glucose levels were measured with 
point-of-care blood gas analyzers or laboratory 
analyzers that were in routine use at each center. 
The analyzers were maintained according to NHS 
quality standards (www.cpa-uk.co.uk/dpmed.htm); 
all laboratories were registered with Clinical 
Pathology Accreditation (United Kingdom). Dur-
ing recruitment, the treatment assignments were 
blinded; however after randomization, the inves-
tigators were aware of the group assignments.
PATIENT EVALUATION
Evaluation of Risk
Baseline demographic and clinical characteristics 
were recorded. For patients who had undergone 
cardiac surgery (cardiac-surgery subgroup), the 
score on the Risk Adjustment in Congenital 
Heart Surgery (RACHS-1, on which scores range 
from 1 to 6, with higher scores indicating greater 
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risk)13 was assessed. For children who had been 
admitted to the pediatric ICU for other reasons 
(non–cardiac-surgery subgroup), the score on the 
Paediatric Index of Mortality 2 (PIM2, on which 
scores range from 0 to 100, with higher scores 
indicating a higher risk of death)14 was assessed.
Outcome Measures
Outcome measures were defined and statistical 
analyses were prespecified in the statistical analy-
sis plan.12 The primary outcome was the number 
of days alive and free from mechanical ventila-
tion at 30 days after randomization.15 Secondary 
outcomes were assessed at two time points. At 
the time of discharge from the pediatric ICU (or 
at 30 days if the child was in the pediatric ICU for 
>30 days), we recorded the number of days in the 
pediatric ICU, vital status, duration of mechani-
cal ventilation and of receipt of vasoactive drugs, 
status with respect to the need for renal-replace-
ment therapy, incidence of bloodstream infection, 
use of antibiotics for more than 10 days, number 
of red-cell transfusions, Paediatric Logistic Organ 
Dysfunction (PELOD) score,16,17 rate of readmis-
sion to the pediatric ICU, length of stay in the 
hospital, and costs. At 12 months after random-
ization, we assessed the length of stay in the 
pediatric ICU and hospital (including during re-
admissions), vital status, and costs of hospital 
and community health services. Data on readmis-
sions to the original pediatric ICU were recorded 
on the case-report forms. Data on readmissions 
other than to the original ICU and use of pri-
mary and community health services were ob-
tained from a questionnaire that was mailed 
to parents at 12 months. All costs are reported on 
the basis of 2010–2011 hospital charges.
Serious Adverse Events
Moderate hypoglycemia was defined as a blood 
glucose level of 36 to 45 mg per deciliter (2.0 to 
2.5 mmol per liter). Severe hypoglycemia was de-
fined as a blood glucose level lower than 36 mg 
per deciliter. The details of each hypoglycemic or 
other adverse event were reviewed by the clinical 
coordinating center and managed in compliance 
with the U.K. Medicines for Human Use (Clinical 
Trials) Regulations 2004.
STATISTICAL ANALYSIS
A difference of 2 days in the number of days free 
from mechanical ventilation at 30 days was con-
sidered to be clinically important. On the basis of 
data from the U.K. Paediatric Intensive Care Audit 
Network for 2003–2004,18 a standard deviation 
of 7 days was assumed for both trial groups. We 
calculated that with a sample size of 1500, the 
study would have 80% power for an interaction 
test to detect a 2-day difference in the effect of 
the intervention between the cardiac-surgery sub-
group and the non–cardiac-surgery subgroup, at 
a 5% level of significance.
Analyses were performed according to the 
intention-to-treat principle. For the primary out-
come, linear regression models were used to esti-
mate the mean between-group difference in the 
number of days free from mechanical ventilation 
at 30 days. For the secondary outcomes, appro-
priate generalized models were used. Odds ra-
tios and mean differences are reported with 95% 
confidence intervals. Where there was evidence 
of nonnormality in the continuous outcome mea-
sures, nonparametric bootstrapping was used to 
estimate bias-corrected confidence intervals.19
Six subgroup analyses were prespecified for 
subgroups defined according to the following 
variables: admission to the pediatric ICU after 
cardiac surgery versus admission for other reasons, 
age (<1 year vs. 1 to 16 years), RACHS-1 score 
(1 through 4 vs. 5 and 6), PIM2 score for risk of 
death (<5%, 5 to <15%, and ≥15%), status with 
respect to traumatic brain injury, and “run-in” 
patients (i.e., the first 100 children who under-
went randomization) versus patients who under-
went randomization subsequently. Evidence of any 
differential effects of the intervention on the pri-
mary outcome, according to subgroup, was as-
sessed with the use of likelihood ratio tests for 
the treatment-by-subgroup interaction terms. The 
effects in the various subgroups were estimated 
directly from the regression model with the inter-
action term included.
The difference in costs between tight glyce-
mic control and conventional glycemic control 
were reported at 30 days and at 12 months, for the 
two groups overall and for the cardiac-surgery 
subgroup as compared with the non–cardiac-sur-
gery subgroup. Missing data on cost at 12 months 
were handled with multiple imputation.20-22 Im-
putation models included baseline covariates, 
the number of days mechanical ventilation was 
used, total length of stay in the hospital (includ-
ing ICU), and costs at 30 days, as well as infor-
mation on 12-month costs for children for whom 
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1384 Underwent randomization
19,924 Patients were assessed for eligibility
15,483 Were ineligible
565 Had gestation <36 wk
211 Were >16 yr of age
56 Had diabetes mellitus
268 Had established or suspected diagnosis of inborn
error of metabolism
312 Had treatment withdrawal or limitation
135 Were inpatient on PICU/CICU for >5 consecutive
days
262 Had already participated in CHiP trial during
previous admission
2285 Were not likely to continue mechanical ventilation 
and vasoactive support drugs beyond 12 hr
1576 Did not have arterial catheter in place
23 Had parent or guardian who declined to participate
143 Died
18 Were not recruited within time frame
104 Had other reasons
2637 Did not undergo ventilation
9601 Were not receiving vasoactive drugs 
694 Were assigned to tight glycemic control
4441 Were considered potentially eligible
for trial
3057 Did not undergo randomization
1093 Had parent or guardian who declined to participate
513 Were not recruited within time frame
1469 Had other reasons
7 Had protocol violations 8 Had protocol violations
461 Received insulin
233 Did not receive insulin
109 Received insulin
566 Did not receive insulin
675 Were assigned to conventional 
glycemic control
622 Were potentially eligible
for 12-mo follow-up
72 Died
35 <30 days
37 ≥30 days to <12 mo
68 Died
34 <30 days
34 ≥30 days to <12 mo
607 Were potentially eligible
for 12-mo follow-up
292 Were excluded
1 Had parent or guardian 
   who declined to 
   participate
202 Had data administratively
censored before 12 mo
89 Were ineligible for
12-mo follow-up
278 Were excluded
194 Had data administratively
censored before 12 mo
84 Were ineligible for
12-mo follow-up
330 Had questionnaire sent to parent or guardian
123 Parent or guardian did not respond to questionnaire
207 (62.7%) Parent or guardian responded to questionnaire
329 Had questionnaire sent to parent or guardian
128 Parent or guardian did not respond to 
       questionnaire
201 (61.1%) Parent or guardian responded to
       questionnaire
694 Had data available for primary outcome 675 Had data available for primary outcome
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this end point was assessed. Sensitivity analyses 
were performed to assess the between-group 
differences in costs at 12 months according to 
assumptions about whether additional costs for 
insulin therapy and the monitoring of glycemic 
control were included, whether unit costs were 
taken from all pediatric ICUs in England (not 
just those in the CHiP trial), and whether costs 
were assumed to follow a gamma distribution 
rather than a normal distribution.
R esult s
STUDY PARTICIPANTS
Participants were recruited between May 4, 2008, 
and August 31, 2011, at which time funding for 
recruitment ceased. A total of 19,924 children 
were screened at 13 sites, and 1369 eligible chil-
dren were randomly assigned to a study group: 
694 to tight glycemic control and 675 to conven-
tional glycemic control (Fig. 1). The baseline 
characteristics of the groups were similar (Table 1, 
and Table S1 in the Supplementary Appendix, 
available at NEJM.org). A total of 60% of the chil-
dren had been admitted to the pediatric ICU after 
having undergone cardiac surgery.
INSULIN ADMINISTRATION AND TREATMENT EFFECTS
More patients in the tight-glycemic-control group 
than in the conventional-glycemic-control group re-
ceived insulin (461 of 694 patients [66.4%] vs. 109 of 
675 patients [16.1%], P<0.001). Patients in the tight-
glycemic-control group, as compared with those in 
the conventional-glycemic-control group, received 
more insulin while they were in the hospital (mean, 
0.18 vs. 0.07 IU per kilogram of body weight per 
day) and for a longer duration (3.2 days vs. 1.7 days) 
and had lower mean daily blood glucose levels 
during the 10 days after randomization (Fig. 2, 
and Table S2 in the Supplementary Appendix). The 
mean caloric intake was similar in the two groups.
OUTCOMES
Status at 30 Days after Randomization
The mean between-group difference in the num-
ber of days alive and free from mechanical venti-
lation at 30 days was 0.36 days (95% confidence 
interval [CI], −0.42 to 1.14) (Table 2). Secondary 
outcomes were similar in the two groups at 30 days 
after randomization, although a lower proportion 
of patients in the tight-glycemic-control group 
received renal-replacement therapy (odds ratio, 
0.63; 95% CI, 0.45 to 0.89). None of the interac-
tion tests between the intervention and prespeci-
fied subgroups were significant: P = 0.63 for the 
comparison of patients who had undergone car-
diac surgery with those who had not (between-
group difference, –0.37 days; 95% CI, –1.92 to 
1.17); P = 0.28 for the comparison of patients 
younger than 1 year of age with those 1 year of 
age or older (between-group difference, 0.88 days; 
95% CI, –0.72 to 2.49); P = 0.09 for the comparison 
of patients who had a RACHS-1 score of 1 through 
4 with those who had a score of 5 and 6 (be-
tween-group difference, 2.78 days; 95% CI, –0.33 
to 5.99); P = 0.88 for the overall comparison of 
patients who had a PIM2 score of less than 5% 
with those who had a score of 5% to less than 
15% and those who had a score of 15% or higher 
(between-group differences, 0.77 days; 95% CI, 
–4.19 to 2.65; and –1.74 days; 95% CI, –6.06 to 
2.58); and P = 0.66 for the comparison between 
run-in patients and non–run-in patients (between-
group difference, 0.67 days; 95% CI, –2.33 to 
3.66). Since there were only 13 cases of traumatic 
brain injury, no tests of interaction were per-
formed for this subgroup.
Adverse Events and Serious Adverse Events
A total of 135 patients had at least one episode of 
hypoglycemia; 61 of these had one or more se-
vere episodes (Table 2). Hypoglycemia occurred 
in 33 of the 799 patients (4.1%) who did not re-
ceive insulin and in 102 of the 570 patients 
(17.9%) who did receive insulin. The proportion 
of patients with hypoglycemia was greater in the 
tight-glycemic-control group than in the conven-
tional-glycemic-control group (moderate hypo-
glycemia, 12.5% vs. 3.1%; P<0.001; and severe 
hypoglycemia, 7.3% vs. 1.5%; P<0.001). Of the 
135 patients who had at least one episode of hy-
Figure 1 (facing page). Screening, Randomization,  
Assessment, and Follow-up.
Patients could have more than one reason for ineligi-
bility for the study. Information on vital status up to 
12 months was available for all patients, with the ex-
ception of 17 non-U.K. nationals, from the U.K. Office 
of National Statistics. Owing to funding constraints, 
the 12-month follow-up assessment was performed 
only for patients who underwent randomization up to 
October 30, 2010 (i.e., the follow-up was administra-
tively censored). CHiP denotes Control of Hypergly-
caemia in Paediatric Intensive Care, CICU cardiac inten-
sive care unit, and PICU pediatric intensive care unit.
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poglycemia, 8 (5.9%) had a seizure on the same 
day; all 8 were in the tight-glycemic-control group.
A total of 11.1% of the patients who had at 
least one hypoglycemic episode died, as com-
pared with 4.4% of those who did not have any 
hypoglycemic episodes (P = 0.001). In the sub-
group of patients who had undergone cardiac 
surgery, 10.6% of the patients who had at least 
one hypoglycemic episode died, as compared 
with 2.1% of those who did not have any hypo-
glycemic episodes (P<0.001). In contrast, there 
was no excess mortality attributable to hypogly-
cemia in the subgroup that had not undergone 
cardiac surgery: 11.6% of patients with at least 
one hypoglycemic episode died, as compared 
with 8.2% of those who did not have any hypo-
glycemic episodes (P = 0.35).
In both the cardiac-surgery and non–cardiac-
surgery subgroups, hypoglycemia occurred in a 
greater proportion of patients in the tight-glycemic-
control group than in the conventional-glycemic-
control group. Among patients who had under-
gone cardiac surgery, moderate hypoglycemia 
occurred in 10.9% of the patients in the tight-
glycemic-control group versus 1.4% in the conven-
tional-glycemic-control group (P<0.001); severe 
hypoglycemia occurred in 5.5% versus 0.5% 
(P<0.001). Among patients who had not under-
gone cardiac surgery, moderate hypoglycemia 
occurred in 15.4% of the patients in the tight-
glycemic-control group versus 5.8% in the con-
ventional-glycemic-control group (P<0.001); severe 
hypoglycemia occurred in 10.3% versus 3.1% 
(P = 0.001). Patients in the cardiac-surgery sub-
group who received insulin were not at greater 
risk for hypoglycemia than were those in the 
non–cardiac-surgery subgroup who received insu-
lin (16.4% and 20.3% with hypoglycemia in the 
two subgroups, respectively).
Costs at 30 Days and Hospitalization through 90 Days
The mean costs at 30 days after randomization 
were similar in the two study groups, both over-
all and in the cardiac-surgery subgroup. In the 
subgroup that had not undergone cardiac sur-
gery, the mean costs were lower with tight glyce-
mic control than with conventional glycemic con-
trol (Table S3 in the Supplementary Appendix).
The proportion of patients still in the hospital 
at each time point after randomization was 
similar in the two study groups, both overall 
(P = 0.48 by the log-rank test for the comparison 
at 90 days) and in the cardiac-surgery subgroup 
(P = 0.17) (Fig. 3). In the subgroup that had not 
undergone cardiac surgery, fewer patients in the 
tight-glycemic-control group than in the conven-
tional-glycemic-control group remained in the 
hospital at 30 days, 60 days, and 90 days after 
randomization (P = 0.006 for the 90-day compari-
son) (Fig. 3).
Deaths, Hospitalizations, and Costs  
at 12 Months
The number of deaths at 12 months was similar 
in the two groups (73 in the tight-glycemic-con-
trol group and 71 in the conventional-glycemic-
control group; hazard ratio with tight glycemic 
control, 1.00; 95% CI, 0.72 to 1.39; P = 0.99 by the 
log-rank test). The corresponding subgroup haz-
ard ratios were 1.02 (95% CI, 0.61 to 1.68) in the 
Table 1. Baseline Characteristics of the Study Patients.*
Characteristic
Tight  
Glycemic  
Control
(N = 694)
Conventional  
Glycemic  
Control
(N = 675)
Age — no. (%)
0 to <1 yr 432 (62.2) 421 (62.4)
1 to 16 yr 262 (37.8) 254 (37.6)
Reason for admission to pediatric 
ICU — no. (%)
Cardiac surgery 421 (60.7) 416 (61.6)
Other reason 273 (39.3) 259 (38.4)
RACHS-1 score — no./total no. (%)†
1 through 4 388/421 (92.2) 393/416 (94.5)
5 or 6 33/421 (7.8) 23/416 (5.5)
PIM2 score — no./total no. (%)‡
<5% 74/273 (27.1) 67/259 (25.9)
5% to <15% 144/273 (52.7) 144/259 (55.6)
≥15% 55/273 (20.1) 48/259 (18.5)
* There were no significant differences (at P<0.05) between the two groups in 
any of the characteristics. All the categories of characteristics listed here were 
factors in a minimization algorithm that was used to balance the study-group 
assignments. ICU denotes intensive care unit.
† Scores on the Risk Adjustment in Congenital Heart Surgery (RACHS-1)13 range 
from 1 to 6, with higher scores indicating greater risk. The RACHS-1 was as-
sessed in the subgroup of patients who had undergone cardiac surgery.
‡ Scores on the Paediatric Index of Mortality (PIM2)14 provide an estimate of 
the risk of death; scores range from 0 to 100, with higher scores indicating a 
higher estimated risk of death. The PIM2 was assessed in the subgroup of pa-
tients who had been admitted to the pediatric ICU for reasons other than car-
diac surgery.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on January 15, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Hyperglycemic Control in Pediatric Intensive Care
n engl j med 370;2 nejm.org january 9, 2014 113
M
ea
n 
B
lo
od
 G
lu
co
se
 (m
g/
dl
)
120
125
115
110
100
105
0
0 2 4 6 8 10
B
C
A
Conventional glycemic control
Tight glycemic control
Days since Randomization
In
tr
av
en
ou
s 
C
al
or
ie
s 
(k
ca
l/
kg
/d
ay
)
40
50
30
20
10
0
1 2 3 4 5 6
Days since Randomization
En
te
ra
l C
al
or
ie
s 
(k
ca
l/
kg
/d
ay
)
80
100
60
40
20
0
1 2 3 4 5 6
Conventional glycemic control Tight glycemic control
Conventional glycemic control Tight glycemic control
Days since Randomization
 
 
 
 
 
 
 
 
 
 
Figure 2. Blood Glucose Level and Caloric Intake, According to Treatment Group.
Panel A shows the mean blood glucose levels for the first 10 days after randomization, with vertical bars indicating 
95% confidence intervals. To convert the values for glucose to millimoles per liter, multiply by 0.05551. Day 1 data 
are the average levels from the time of randomization to the end of the day of randomization. The target range of 
blood glucose levels with tight glycemic control was 72 to 126 mg per deciliter. The target blood glucose level with 
conventional glycemic control was less than 216 mg per deciliter. The daily intake of calories intravenously and 
 enterally is shown in Panels B and C, respectively. The horizontal lines within the boxes indicate medians, the upper 
and lower ends of the boxes indicate the 75th and 25th percentiles, respectively, and the whiskers indicate the ranges.
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cardiac-surgery subgroup and 0.98 (95% CI, 0.63 
to 1.51) in the non–cardiac-surgery subgroup. 
The time from randomization to death was also 
similar in the two study groups — overall, in the 
subgroup that had undergone cardiac surgery, 
and in the subgroup that had not undergone car-
diac surgery (Fig. S1 in the Supplementary Ap-
pendix).
In the cardiac-surgery subgroup, the average 
length of stay in the hospital up to 12 months 
after randomization was 20 days in each of the 
two study groups (Table S4 in the Supplemen-
tary Appendix). In the subgroup that had not 
undergone cardiac surgery, the corresponding 
length of stay was, on average, 13.5 days shorter 
with tight glycemic control than with conven-
tional glycemic control (Table S4 in the Supple-
mentary Appendix).
Overall, the mean 12-month costs were lower 
in the tight-glycemic-control group than in the 
Table 2. Clinical Outcomes and Adverse Events.*
Outcome
Tight  
Glycemic  
Control
(N = 694)
Conventional 
Glycemic  
Control
(N = 675)
Mean Difference  
(95% CI)
Odds Ratio 
with Tight 
Glycemic Control
(95% CI)
Primary outcome: no. of days alive and free from 
mechanical ventilation at 30 days
23.6±0.3 23.2±0.3 0.36 (−0.42 to 1.14)
Secondary outcomes
Death within 30 days after trial entry — no.  
of patients/total no. (%)
35/693 (5.1) 34/674 (5.0) 1.00 (0.62 to 1.63)
No. of days in pediatric ICU 6.5±0.2 7.0±0.2 −0.47 (−1.12 to 0.15)
No. of days in hospital 16.4±0.3 16.7±0.4 −0.33 (−1.24 to 0.62)
No. of days receiving mechanical ventilation 5.3±0.2 5.6±0.2 −0.31 (−0.87 to 0.25)
PELOD score† 9.8±0.2 9.8±0.2 −0.31 (−0.87 to 0.25)
Median no. of days receiving vasoactive drugs (IQR) 3 (2–6) 4 (2–6) −0.20 (−0.64 to 0.25)
Renal-replacement therapy — no. of patients (%)‡ 62 (8.9) 91 (13.5) 0.63 (0.45 to 0.89)
Bloodstream infection — no. of patients (%)§ 38 (5.5) 43 (6.4) 0.85 (0.54 to 1.34)
Use of antibiotics >10 days — no. of patients (%) 62 (8.9) 74 (11.0) 0.80 (0.56 to 1.14)
No. of red-cell transfusions 1.0±0.1 1.1±0.1 −0.11 (−0.43 to 0.18)
≥1 Moderate or severe hypoglycemic episode —  
no. of patients (%)¶
110 (15.9) 25 (3.7) 4.90 (3.13 to 7.67)
Moderate hypoglycemic episodes
Total no. 127 30
≥1 Episode — no. of patients (%) 87 (12.5) 21 (3.1) 4.46 (2.73 to 7.28)
No. of episodes/patient 0.20±0.03 0.04±0.01 0.14 (0.09 to 0.20)
Severe hypoglycemic episode
Total no. 70 11
≥1 Episode — no. of patients (%) 51 (7.3) 10 (1.5) 5.27 (2.65 to 10.48)
No. of episodes/patient 0.10±0.02 0.02±0.01 0.08 (0.05 to 0.12)
Seizure requiring medication — no. of patients (%) 23 (3.3) 15 (2.2) 1.15 (0.77 to 2.98)
* Plus–minus values are means ±SE. IQR denotes interquartile range.
† Scores on the Paediatric Logistic Organ Dysfunction (PELOD) assessment range from 0 to 71, with higher scores indicating more severe  
organ dysfunction.
‡ Renal-replacement therapy was defined as peritoneal dialysis or hemofiltration.
§ A bloodstream infection was defined as a positive blood culture in association with two or more features of systemic inflammation23 or any 
blood culture that was positive for fungus.
¶ Moderate hypoglycemia was defined as a blood glucose level of 36 to 45 mg per deciliter (2.0 to 2.5 mmol per liter), and severe hypoglyce-
mia as a blood glucose level of less than 36 mg per deciliter. Patients may have had both a moderate episode and a severe episode.
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Figure 3. Proportion of Patients Remaining in the Hospital, from the Time of the Index Admission to 180 Days  
after Randomization, According to Treatment Group.
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conventional-glycemic-control group (difference 
in cost per patient, −$4,815; 95% CI, −10,298 to 
668) (Table S2 in the Supplementary Appendix). 
In the subgroup that had undergone cardiac 
surgery, the costs were similar in the two study 
groups, but in the subgroup that had not under-
gone cardiac surgery, the mean costs were lower 
in the tight-glycemic-control group than in the 
conventional-glycemic-control group, with a dif-
ference in cost of –$13,120 (95% CI, –24,682 to 
–1,559). Sensitivity analyses showed that the re-
sults were robust with respect to the prespeci-
fied assumptions.
Discussion
In this multicenter, randomized trial involving 
critically ill children in pediatric ICUs, tight gly-
cemic control did not increase the number of 
days that children were alive and free from me-
chanical ventilation at 30 days. However, the sec-
ondary outcomes reveal a complex relationship 
of potential benefits and harms. Although tight 
glycemic control was associated with a smaller 
proportion of patients receiving renal-replace-
ment therapy than was conventional glycemic 
control, it resulted in more episodes of hypogly-
cemia. In addition, as compared with conven-
tional glycemic control, tight glycemic control 
was associated with a shorter length of stay in 
the hospital and lower total health care costs at 
12 months; the lower costs appear to be driven 
by results in the subgroup that had not under-
gone cardiac surgery.
Our trial involving a pediatric cohort sought 
to ensure a high degree of internal and external 
validity by concealing the treatment assignment 
during recruitment, by including a range of pe-
diatric ICUs delivering protocols that fit within 
routine clinical practice (“pragmatic” design), by 
evaluating both clinical and economic factors 
with follow-up at 12 months, and by following a 
prespecified analysis plan.12 The inability to con-
ceal the group assignments after randomization 
was a limitation of the study. In addition, al-
though the primary end point in the study (free-
dom from mechanical ventilation at 30 days) 
was selected on the basis of the best evidence at 
the time,15,18 our time-to-event analysis indi-
cates that for patients who have not undergone 
cardiac surgery, future trials could assess venti-
lator-free days at later time points. Our trial 
highlights the importance of designing pediatric 
ICU trials with longer-term clinical and economic 
end points, (e.g., hospital stay and costs at 12 
months), especially among patients who have not 
undergone cardiac surgery.
The current study differs from previous stud-
ies of tight glycemic control in children in several 
ways.11,24 First, Vlasselaers et al.11 reported the 
results of a single-center, “early adopter” study 
involving predominantly patients who had under-
gone cardiac surgery, and Agus et al.24 reported 
the results of a 2-center study involving children 
who had undergone cardiac surgery, whereas 
our study recruited children from 13 pediatric 
ICUs and included both patients who had under-
gone cardiac surgery and those who had been 
admitted to the pediatric ICU for other reasons. 
It is possible that clinical outcomes have im-
proved over time; for example, the rate of second-
ary infection was lower in the study by Agus et al., 
in 2012, than in the study by Vlasselaers et al., in 
2009 (5% vs. 33%). Second, Vlasselaers et al. used 
a lower range for tight glycemic control than we 
used in our study, and our insulin dosing was 
closer to the lower dosing reported by Agus et al. 
Vlasselaers et al. reported a benefit of tight gly-
cemic control, whereas Agus et al. did not — 
with the findings of Agus et al. consistent with 
findings in the cardiac-surgery subgroup in our 
study. Finally, our study examined potential dif-
ferences in the effect of tight glycemic control in 
patients who had undergone cardiac surgery as 
compared with patients who had not. We specu-
late that since the outcomes of cardiac surgery 
are currently very good, there is little potential 
for improvement with respect to patients who 
have undergone cardiac surgery, but in patients 
who have not undergone cardiac surgery, stress 
hyperglycemia may be truly detrimental5,25,26; 
hence, tight glycemic control is important.
Hypoglycemia is a major complication of tight 
glycemic control.27 A post hoc analysis of the 
Normoglycemia in Intensive Care Evaluation—
Survival Using Glucose Algorithm Regulation 
(NICE-SUGAR) study indicated that hypoglyce-
mia was associated with increased mortality.28 
In contrast, follow-up of children in the study by 
Vlasselaers et al. at 4 years showed that neither 
hypoglycemia nor tight glycemic control resulted 
in significantly worse neurodevelopmental se-
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quelae than did conventional glycemic con-
trol.29,30 Our finding of increased mortality as-
sociated with hypoglycemia in the cardiac-surgery 
subgroup is consistent with the findings of the 
NICE-SUGAR study and should be considered as 
further evidence to support the use of conven-
tional management of blood glucose levels in 
patients who have undergone cardiac surgery.27 
However, the absence of this association in pa-
tients who had not undergone cardiac surgery, 
together with the absence of an association with 
neurodevelopmental sequelae of hypoglycemia,29 
makes the economic analysis more relevant; the 
reduction in 12-month costs cannot be explained 
by earlier increased mortality. Tight glycemic con-
trol, as compared with conventional glycemic 
control, can lead to an average reduction of 
$13,000 per patient in 12-month costs for children 
who have not undergone cardiac surgery. In the 
NHS, implementing tight glycemic control for 
this subgroup could yield annual savings of ap-
proximately $16 million in pediatric ICUs in the 
United Kingdom. However, this overall benefit 
must be balanced against the risk of hypoglycemia. 
Agus et al. reported a very low rate of severe (but 
not moderate) hypoglycemia, almost certainly ow-
ing to their use of continuous glucose monitoring.24
In conclusion, our study shows that in a popu-
lation of critically ill children, tight glycemic 
control (72 to 126 mg per deciliter) did not have 
a significant effect on major clinical outcomes 
among children admitted to a pediatric ICU after 
cardiac surgery. Among children admitted to a 
pediatric ICU for other reasons, however, tight 
glycemic control, as compared with conventional 
glycemic control, led to a shorter length of stay 
in the hospital and lower health care costs in the 
12 months after randomization. As with any 
trial, further studies would be required to assess 
whether these findings apply to routine clinical 
practice in other settings.27
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